GALE Mouse Monoclonal Antibody [Clone ID: OTI1C4]

CAT#: CF502146

Reviews ()
Write a review

Carrier-free (BSA/glycerol-free) GALE mouse monoclonal antibody, clone OTI1C4 (formerly 1C4)

Formulation: Standard Carrier-Free



USD 600.00

In Stock*

Size
    • 100 ug

Frequently bought together (2)
Biotinylation Labelling Kit formatted 4 x 0.05mg
    • 200 ug

USD 412.00


HRP Conjugation kit for 0.2mg IgG
    • 200 ug

USD 266.00

Other products for "GALE"

Specifications

Product Data
Clone Name OTI1C4
Applications IHC, WB
Recommended Dilution WB 1:500~2000, IHC 1:150
Reactivities Human, Dog, Rat, Monkey, Mouse
Host Mouse
Isotype IgG1
Clonality Monoclonal
Immunogen Full length human recombinant protein of human GALE (NP_000394) produced in HEK293T cell.
Formulation Lyophilized powder (original buffer 1X PBS, pH 7.3, 8% trehalose)
Reconstitution Method For reconstitution, we recommend adding 100uL distilled water to a final antibody concentration of about 1 mg/mL. To use this carrier-free antibody for conjugation experiment, we strongly recommend performing another round of desalting process. (OriGene recommends Zeba Spin Desalting Columns, 7KMWCO from Thermo Scientific)
Purification Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation Unconjugated
Storage Store at -20°C as received.
Stability Stable for 12 months from date of receipt.
Predicted Protein Size 38.1 kDa
Gene Name Homo sapiens UDP-galactose-4-epimerase (GALE), transcript variant 1, mRNA.
Background This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form). Multiple alternatively spliced transcripts encoding the same protein have been identified. [provided by RefSeq, Jul 2008]
Synonyms SDR1E1
Reference Data
Protein Families Druggable Genome
Protein Pathways Amino sugar and nucleotide sugar metabolism, Galactose metabolism, Metabolic pathways
Customer Reviews 
Loading...
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.